Industry news that matters to you.  Learn more

MDxHealth Licenses Biomarkers for Bladder Cancer to Predictive Biosciences

Reading time: 2 minutes

MDxHealth SA, a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has agreed to out-license certain DNA methylation biomarkers to Predictive Biosciences (Lexington, MA) for diagnostic applications in bladder cancer.

Under the agreement, MDxHealth grants Predictive Biosciences exclusive rights for the use of a number of its DNA methylation biomarkers in bladder cancer testing in the United States. MDxHealth retains exclusive worldwide rights to these markers in tissue-based bladder cancer tests. In return, MDxHealth will receive upfront and milestone payments and royalties on net sales. Predictive Biosciences is one of the few diagnostic companies with a strong focus on applications in urologic oncology, including bladder cancer.

“We are pleased to work with Predictive Biosciences, a recognized player in the urologic oncology space, just like our partner Exact Sciences is in colon cancer screening. We believe that collaborating with partners who focus on one specific disease area is a better way to leverage our biomarkers for cancer screening as these dedicated companies stand a greater chance of bringing these products successfully to market,” said Dr. Jan Groen, Chief Executive Officer of MDxHealth.

“Predictive Biosciences is delighted to obtain an exclusive license to MDxHealth’s proprietary DNA methylation biomarkers for use in our bladder cancer programs. These powerful biomarkers can play an important role in rapidly developing an industry-leading diagnostic panel for the management of bladder cancer, a devastating disease for which today physicians have only limited tools at their disposal,” said Peter Klemm, Chief Executive Officer of Predictive Biosciences.

Source: MDxHealth